Leukemia & lymphoma/Leukemia and lymphoma,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 12
Published: Dec. 3, 2024
Advances
in
treating
classic
Hodgkin
lymphoma
(cHL)
have
improved
cure
rates,
with
overall
survival
exceeding
80%,
resulting
a
growing
population
of
survivors
at
risk
long-term
complications,
particularly
cardiac
and
pulmonary
toxicity.
Bleomycin,
key
component
combination
chemotherapy,
is
associated
bleomycin-induced
toxicity
(BPT).
Using
label-free
quantification
nano
liquid
chromatography-tandem
mass
spectrometry,
protein
expression
diagnostic
samples
from
patients
without
BPT
was
compared.
Results
showed
differential
disrupted
cellular
pathways,
suggesting
biological
differences
risk.
Immunohistochemical
analysis
revealed
higher
JAK3,
BID,
MMP9,
lower
CD20,
TPD52,
PIK3R4
BPT.
High
BID
low
CD20
were
inferior
survival,
while
high
JAK3
linked
to
poorer
progression-free
survival.
These
findings
highlight
altered
profiles
pretreatment
cHL
biopsies
development.
BIO Integration,
Journal Year:
2025,
Volume and Issue:
6(1)
Published: Jan. 1, 2025
Pulmonary
fibrosis
(PF)
is
a
progressive
interstitial
lung
disease
characterized
by
excessive
extracellular
matrix
deposition
and
tissue
scarring,
leading
to
impaired
function
respiratory
failure.
Although
current
treatments,
such
as
pirfenidone
nintedanib,
slow
progression,
they
fail
completely
halt
or
reverse
fibrosis.
Therefore,
innovative
therapeutic
strategies
are
needed.
Targeted
drug
delivery
systems
(TDDSs)
emerging
promising
solutions.
Biomaterials
play
critical
roles
in
these
enhancing
specificity,
availability,
efficacy,
while
minimizing
systemic
toxicity.
The
most
notable
biomaterials
include
nanotechnology-based
systems,
including
liposomes
polymeric
nanoparticles,
which
facilitate
penetration
release
fibrotic
tissues.
Hydrogels
have
three-dimensional
structures
providing
controlled
sustained
at
inflammation
sites,
therefore
particularly
valuable
PF
treatment.
Furthermore,
biological
carriers
stem
cells
vesicles
biocompatibility
anti-inflammatory
effects
that
improve
outcomes.
Despite
the
potential
of
clinical
translation
hindered
several
challenges,
immune
clearance,
stability
platforms,
optimization
retention
within
diseased
Interdisciplinary
approaches
integrating
precision
medicine
with
advancements
may
provide
solutions
opening
new
avenues
for
This
review
discusses
developments
targeted
PF,
emphasizing
importance
biomaterials,
mechanisms
barriers
involved
pulmonary
delivery,
future
perspectives
overcoming
limitations.
ultimate
goal
patient
outcomes
revolutionizing
approach
treatment
through
advanced
technologies.
Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(12), P. 1605 - 1605
Published: Nov. 28, 2024
Background/objectives:
Idiopathic
pulmonary
fibrosis
(IPF)
is
a
prevalent
interstitial
lung
disease
that
typically
progresses
gradually,
leading
to
respiratory
failure
and
ultimately
death.
IPF
can
be
treated
with
the
tyrosine
kinase
inhibitor,
nintedanib
(NTD),
owing
its
anti-fibrotic
properties,
which
ameliorate
impairment
of
function.
This
study
aimed
formulate,
optimize,
assess
NTD-loaded
ufasomes
(NTD-UFSs)
as
nanosystem
for
targeting
snowball
bioavailability
therapeutic
efficacy
drug.
Methods:
To
investigate
influence
numerous
factors
on
NTD-UFSs
assembly
determine
optimal
formulation,
Box–Behnken
statistical
design
was
implemented
assistance
Design-Expert®
software.
The
thin-film
hydration
strategy
employed
fabricate
NTD-UFSs.
optimum
formulation
subsequently
selected
subjected
additional
evaluations.
Also,
using
rat
model,
comparative
pharmacokinetic
analysis
scrutinized.
Results:
elicited
an
accumulative
release
65.57%
after
24
h,
encapsulation
efficiency
62.51%,
zeta
potential
−36.07
mV,
vesicular
size
364.62
nm.
In
addition,
it
disclosed
remarkable
stability
continuous
cumulative
pattern.
vivo
histopathological
studies
ascertained
tolerability
administered
intratracheally.
According
studies,
intratracheal
administration
manifested
significantly
higher
AUC0–∞
value
than
oral
NTD
suspensions,
by
approximately
5.66-
3.53-fold,
respectively.
Conclusions:
findings
this
proposed
UFSs
might
promising
nanoparadigm
non-invasive
delivery
NTD.
